APA (7th ed.) Citation

Hwu, W., Lee, H., Peipert, J. D., Zhang, R., Werner, C., Sierra, J. R., . . . Tomazos, I. (2025). Clinically meaningful improvements after gene therapy for aromatic L-amino acid decarboxylase deficiency (AADCd) in the Peabody Developmental Motor Scale, Second Edition (PDMS-2) and correlation with Bayley-III scores and motor milestones. Orphanet Journal of Rare Diseases, 20(1), 1. https://doi.org/10.1186/s13023-025-03584-9

Chicago Style (17th ed.) Citation

Hwu, Wuh-Liang, et al. "Clinically Meaningful Improvements After Gene Therapy for Aromatic L-amino Acid Decarboxylase Deficiency (AADCd) in the Peabody Developmental Motor Scale, Second Edition (PDMS-2) and Correlation with Bayley-III Scores and Motor Milestones." Orphanet Journal of Rare Diseases 20, no. 1 (2025): 1. https://doi.org/10.1186/s13023-025-03584-9.

MLA (9th ed.) Citation

Hwu, Wuh-Liang, et al. "Clinically Meaningful Improvements After Gene Therapy for Aromatic L-amino Acid Decarboxylase Deficiency (AADCd) in the Peabody Developmental Motor Scale, Second Edition (PDMS-2) and Correlation with Bayley-III Scores and Motor Milestones." Orphanet Journal of Rare Diseases, vol. 20, no. 1, 2025, p. 1, https://doi.org/10.1186/s13023-025-03584-9.